Connect Biopharma Holdings Ltd (CNTB) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CNTB currently has 63M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 14.04% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
F-3 filing: This F-3 filing describes a plan of distribution for selling securityholders to dispose of their Ordinary Shares through various market methods. |
63M | 0 |
| May 12, 2026 |
10-Q filing | 63.0M shares outstanding |
63M | 0 |
| Mar 31, 2026 |
10-K filing | 55.7M shares outstanding |
56M | 0 |
| Mar 30, 2026 |
8-K filing: Connect Biopharma Holdings Limited entered into a securities purchase agreement for the private placement of 6,130,000 ordinary shares at a price of $3.25 per share, with aggregate gross proceeds expected to be approximately $20.2 million. ($20.2M proceeds) |
55M | 0 |
| Sep 10, 2025 |
POS AM filing: The filing is a prospectus supplement for a shelf offering, allowing the company to offer and sell up to $300,000,000 in various securities, including ordinary shares, preferred shares, debt securities, and purchase contracts from time to time. |
55M | 0 |
| Aug 13, 2025 |
10-Q filing | 55.5M shares outstanding |
55M | 0 |
| Jun 10, 2025 |
F-3 filing: The company is filing an F-3 to offer and sell up to $300,000,000 in various securities, including ordinary shares, American depositary shares, preferred shares, debt securities, and purchase contracts, from time to time in one or more offerings, and ADSs up to $150,000,000 in an at-the-market offering. |
56M | 0 |
| May 15, 2025 |
10-Q filing | 55.4M shares outstanding |
55M | 0 |
| Mar 31, 2025 |
10-K filing | 55.2M shares outstanding |
55M | 0 |
| Apr 16, 2024 |
20-F filing | 55.1M shares outstanding |
55M | 0 |
| Apr 11, 2023 |
20-F filing | 55.0M shares outstanding |
55M | 35K |
| Apr 15, 2022 |
F-3 filing: Connect Biopharma Holdings Limited may offer and sell up to $300,000,000 of American Depositary Shares representing ordinary shares, and up to $150,000,000 in an at-the-market offering through sales agents SVB Leerink and Cantor. |
55M | 0 |
| Mar 31, 2022 |
20-F filing | 55.1M shares outstanding |
55M | 0 |